Sanofi snaps up Ablynx for 3.9bn euros
Sanofi has announced its intention to buy Belgian drugmaker Ablynx via a deal valued at around 3.9 billion Euros, beating Novo Nordisk to the finish line.
Read More
Tag: nanobodies
Sanofi, Ablynx sign $2.7bn research, licensing pact
Sanofi has signed a research pact and licensing deal with Ablynx that could bring as much as $2.7 billion euros to the Belgian biotech’s coffers if all targets are met.
Read More
- UCB and Cancer Research UK form expanded alliance to advance novel cancer therapies
- Calla Lily Clinical Care begins dosing in trial of intravaginal platform for threatened miscarriage
- Palisade Bio reports phase 1a/b data showing colon‑targeted exposure
- MimiVax and Roswell Park open phase 2 trial of SurVaxM for metastatic neuroendocrine tumours
- Myomaker Bio unveils lab‑grown human muscle platform to transform drug testing
